IDEAS home Printed from https://ideas.repec.org/a/spr/drugsa/v44y2021i1d10.1007_s40264-020-01008-0.html
   My bibliography  Save this article

Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations

Author

Listed:
  • Tanja Peters

    (Boehringer Ingelheim)

  • Nigel Soanes

    (AstraZeneca PLC)

  • Maya Abbas

    (Johnson & Johnson Middle East)

  • Jabeen Ahmad

    (Innovate PV)

  • Jean-Christophe Delumeau

    (Bayer Pharma)

  • Esteban Herrero-Martinez

    (AbbVie Ltd)

  • Mélanie Paramananda

    (Pierre Fabre Médicament)

  • Johanna Piper

    (Roche Products Ltd)

  • Fairouz Smail-Aoudia

    (Pierre Fabre Médicament)

  • Willemijn Spuij

    (Bristol Myers Squibb)

  • Tina Veizovic

    (Takeda)

  • Gillian Winstanley

    (Amgen Canada Inc)

Abstract

Pharmaceutical legislation provides a legal framework to ensure the safe and effective use of medicines. This framework requires national regulatory authorities (NRAs) to establish and maintain a pharmacovigilance system (PV system) stating and enforcing the regulatory commitments that key stakeholders, including marketing authorisation holders (MAHs), are required to fulfil. In recent years, national legislative bodies and NRAs across the world have issued a significant amount of legislation and guidance enforcing the obligation to perform pharmacovigilance activities. In countries where the NRA is a member of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH), safety management requirements are generally consistent with ICH guidelines. In a number of countries beyond this scope, requirements may deviate from internationally agreed standards, adding a substantial complexity and increasing burden on the stakeholders involved, whilst the benefit for patients’ safety may not be evident. Committed to fulfilling safety-regulatory obligations in any country where a product licence is held, global pharmaceutical companies have accumulated a broad and deep experience acquired whilst meeting the expectations of a large array of diverse PV systems across the world. These range from sub-optimal frameworks, according to the World Health Organization (WHO) Global Benchmarking Tool, to highly effective resource-optimised PV systems. In order to support countries creating or further developing their PV systems, especially where infrastructure and resources are limited, the European Federation of Pharmaceutical Industries and Associations (EFPIA) International Pharmacovigilance Group (IPVG) has developed consensus recommendations consistent with harmonised standards for the development and step-wise implementation of key PV system components. These recommendations endorsed by the EFPIA membership constitute the focus of this review article.

Suggested Citation

  • Tanja Peters & Nigel Soanes & Maya Abbas & Jabeen Ahmad & Jean-Christophe Delumeau & Esteban Herrero-Martinez & Mélanie Paramananda & Johanna Piper & Fairouz Smail-Aoudia & Willemijn Spuij & Tina Veiz, 2021. "Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations," Drug Safety, Springer, vol. 44(1), pages 17-28, January.
  • Handle: RePEc:spr:drugsa:v:44:y:2021:i:1:d:10.1007_s40264-020-01008-0
    DOI: 10.1007/s40264-020-01008-0
    as

    Download full text from publisher

    File URL: http://link.springer.com/10.1007/s40264-020-01008-0
    File Function: Abstract
    Download Restriction: Access to the full text of the articles in this series is restricted.

    File URL: https://libkey.io/10.1007/s40264-020-01008-0?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    As the access to this document is restricted, you may want to search for a different version of it.

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:spr:drugsa:v:44:y:2021:i:1:d:10.1007_s40264-020-01008-0. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.springer.com/economics/journal/40264 .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.